 Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under 5 deaths annually. Safe, effective Rotavirus vaccines have been available for over a decade and are used in over 98 countries. Several new Rotavirus vaccines have attained national licensure, Rotovac, Bharat Biotech, Rotosal, Serum Institute of India, and Rotavin M1, Polovac, licensed and manufactured in India and Vietnam respectively. All three vaccines have demonstrated safety and efficacy against Rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development. This article was authored by Annika Skansberg, Molly Sauer, Marisa Tan, and others. We are article.tv, links in the description below.